Breaking Finance News

Heron Therapeutics Inc (NASDAQ:HRTX) has been downgraded to Sell in a report by Zacks Investment Research today.

Zacks Investment Research has downgraded Heron Therapeutics Inc (NASDAQ:HRTX) to Sell in a report released on Wednesday October 05, 2016.

Previously on 10/4/2016, Brean Capital reported on Heron Therapeutics Inc (NASDAQ:HRTX) increased the target price from $0.00 to $41.00. At the time, this indicated a possible upside of 1.47%.

Just yesterday Heron Therapeutics Inc (NASDAQ:HRTX) traded -1.17% lower at $16.09. The company’s 50-day moving average is $18.62 and its 200-day moving average is $18.90. The last stock close price is down -10.93% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 638,526 shares of the stock were exchanged, down from an average trading volume of 734,138

See Chart Below

Heron Therapeutics Inc (NASDAQ:HRTX)

Heron Therapeutics Inc has a 52 week low of $15.13 and a 52 week high of $31.32 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 9 firms have issued a report on the stock. The consensus target price is $46.11 with 4 firms rating the stock a strong buy, 4 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

General Information About Heron Therapeutics Inc (NASDAQ:HRTX)

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.